Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.

ABSTRACT:

Introduction

Contemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.

Methods

We characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the en

SUBMITTER: Jarsberg LG 

PROVIDER: S-EPMC8099102 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature